

Special Issue

Mining Actinomycetes for New Antimicrobial Agents

Message from the Guest Editor

The rapid emergence of antimicrobial resistance has created an urgent need for new therapeutic agents with novel modes of action. Actinomycetes remain one of the most prolific sources of clinically important antibiotics and structurally diverse natural products. This Special Issue, "Mining Actinomycetes for New Antimicrobial Agents," aims to highlight recent advances in the discovery, characterization, and development of new antimicrobial compounds. We invite original research articles, reviews, and short communications that explore innovative strategies such as genome mining, metagenomics, synthetic biology, and metabolomics, as well as research from extreme environments, to unlock silent biosynthetic gene clusters and expand the antimicrobial pipeline. Contributions addressing novel bioactive compounds, biosynthetic pathways, strain improvement, mechanisms of action, and applications against drug-resistant pathogens are particularly welcome.

Guest Editor

Dr. Elisa Binda

Department of Biotechnology and Life Sciences, University of Insubria,
21100 Varese, Italy

Deadline for manuscript submissions

30 November 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/268856

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)